FDA guidance
Alternative Procedures for Blood and Blood Components During the COVID-19 Public Health…
FDA guidance · Final · issued Apr 2, 2020
Key facts
| Title | Alternative Procedures for Blood and Blood Components During the COVID-19 Public Health Emergency: Guidance for Industry |
|---|---|
| Status | Final |
| Issue date | Apr 2, 2020 |
| Center | Center for Biologics Evaluation and Research |
| Issuing office | Center for Biologics Evaluation and Research |
| Communication type | Guidance Document |
| Regulated product | Biologics |
| Topics | Public Awareness |
| Docket number | FDA-2020-D-1137 |
| Open for comment | No |
| Document on fda.gov | fda.gov |
At a glance
- None Product codes referenced
- None Recognized standards referenced
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA guidance documents
FDA guidance documents describe the agency's current thinking on regulatory topics. Drafts are issued for comment before a final version is published.
Source: U.S. Food and Drug Administration (FDA), Guidance Documents